Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 5,569 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Degenerative Conditions, Neurologic Clear all
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Obesity and Pediatric Multiple Sclerosis

NCT04593082
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 20 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PET Imaging in ALS Patients

NCT02236897
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
PET Scanning
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 30, 2026, 10:32 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Quantitative Measurement of Nutritional Substrate Utilization in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT00714220
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases
Interventions
Not listed
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
20 Years to 85 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 30, 2026, 10:32 PM EDT
Active, not recruiting Phase 3 Interventional

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

NCT06553027
View directory record Official record
Conditions
Parkinson Disease
Interventions
CVN424 75 mg, CVN424 150 mg, Placebo
Drug
Lead sponsor
Cerevance
Industry
Eligibility
30 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aliso Viejo, California + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 30, 2026, 10:32 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study

NCT05677880
View directory record Official record
Conditions
CADASIL
Interventions
Study Procedures
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

P3 (Prepared, Protected, emPowered)

NCT03320512
View directory record Official record
Conditions
Sexually Transmitted Diseases, Safe Sex, Adherence, Medication
Interventions
P3+, Control
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 24 Years · Male only
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
9
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 30, 2026, 10:32 PM EDT
Terminated Phase 2 Interventional

Lutein and Alzheimer's Disease Study

NCT00596024
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
lutein/zeaxanthin, placebo
Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
55 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Phase 1 Interventional

Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy

NCT02362438
View directory record Official record
Conditions
Giant Axonal Neuropathy, Gene Transfer
Interventions
scAAv9/JeT-GAN
Genetic
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
3 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Not applicable Interventional Results available

The STEP 4Life Trial

NCT05069155
View directory record Official record
Conditions
Alzheimer Disease, At Risk, Alzheimer Disease, Protection Against, Dementia
Interventions
Gamification
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 30, 2026, 10:32 PM EDT
Terminated Phase 2 Interventional Results available

Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease

NCT01789047
View directory record Official record
Conditions
Idiopathic Parkinson's Disease, Drug Induced Dyskinesia
Interventions
Topiramate, Placebo, Amantadine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
30 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 30, 2026, 10:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)

NCT00040378
View directory record Official record
Conditions
Alzheimer Disease
Interventions
alphatocopherol, Selenium, Placebo replacement for vitamin E, Placebo replacement for Selenium
Drug
Lead sponsor
Frederick Schmitt
Other
Eligibility
60 Years to 90 Years · Male only
Enrollment
4,246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2016
U.S. locations
84
States / cities
Birmingham, Alabama • Anchorage, Alaska • Chula Vista, California + 70 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Results available

A Study of Semagacestat for Alzheimer's Patients

NCT01035138
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
semagacestat
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Phase 2 Interventional

MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients

NCT04032626
View directory record Official record
Conditions
Cognitive Impairment, Mild, Cognitive Dysfunction, Amyloid Plaque, Neurodegeneration, Inflammation, Brain
Interventions
Lenalidomide 10 mg, Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
50 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Phoenix, Arizona • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 30, 2026, 10:32 PM EDT
Not yet recruiting Not applicable Interventional

Vibrotactile Coordinated Reset (VCR): A Treatment for Early Stage Parkinson's Disease

NCT05545826
View directory record Official record
Conditions
Parkinson Disease
Interventions
Vibrotactile coordinated reset
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 30, 2026, 10:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multi-limb Dual-task Control in Parkinson's Disease

NCT03662009
View directory record Official record
Conditions
Parkinson Disease
Interventions
multilimb dual task
Other
Lead sponsor
A.T. Still University of Health Sciences
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 30, 2026, 10:32 PM EDT
Terminated Phase 3 Interventional Results available

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

NCT00519532
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
St. Petersburg, Florida • Salisbury, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis

NCT04735432
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
efgartigimod PH20 SC, efgartigimod IV
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
14
States / cities
Carlsbad, California • Orange, California • Boca Raton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Not applicable Interventional Results available

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease

NCT00348309
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Placebo, Donepezil
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
41
States / cities
Litchfield Park, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 30, 2026, 10:32 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Telemedicine Clinical Trial for Cognitive Behavioral Therapy in Familial Dysautonomia

NCT03911063
View directory record Official record
Conditions
Familial Dysautonomia
Interventions
CBT sessions, Talking Sessions
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Phase 2 Interventional

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01491932
View directory record Official record
Conditions
Dyskinesias, Parkinson Disease, Movement Disorders, Parkinsonian Disorders, Anti-Dyskinesia Agents
Interventions
AFQ056
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Englewood, Colorado • Kansas City, Kansas • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 30, 2026, 10:32 PM EDT
Completed No phase listed Observational

Impact of Swallowing Impairment on Individuals With Parkinson Disease

NCT04769843
View directory record Official record
Conditions
Parkinson Disease, Dysphagia
Interventions
Not listed
Lead sponsor
Northern Arizona University
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Flagstaff, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Phase 4 Interventional Results available

The Feasibility of Florbetapir Quantitation

NCT01946243
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Florbetapir F18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Not listed
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 30, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Results available

An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

NCT02649608
View directory record Official record
Conditions
Parkinson Disease
Interventions
0.04 mg Lu AE04621, 0.08 mg Lu AE04621, 0.2 mg Lu AE04621, 0.4 mg Lu AE04621, 0.6 mg Lu AE04621, 0.8 mg Lu AE04621, 1.0 mg Lu AE04621, 1.2 mg Lu AE04621
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
45 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Hallandale, Florida • Orlando, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 30, 2026, 10:32 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Visual Motor Coordination

NCT00568243
View directory record Official record
Conditions
Healthy Volunteer, Neurodegenerative Diseases
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 30, 2026, 10:32 PM EDT